Table 2.
Penetration coefficient of gliclazide in the brain tissue after intra-arterial application of gliclazide (K b/p).
| Groups | Group 1: healthy Gliclazide n = 6 |
Group 2: healthy Gliclazide + DA n = 6 |
Group 3: diabetic Gliclazide n = 6 |
Group 4: diabetic Gliclazide + DA n = 6 |
|
|---|---|---|---|---|---|
| K b/p—mean ± SD | BS | 0.09 ± 0.06 | 1.35 ± 0.92* | 2.13 ± 1.41# | 6.15 ± 4.74××,× |
| C | 0.13 ± 0.06 | 6.23 ± 3.95* | 4.40 ± 2.93# | 14.05 ± 8.53×× | |
| LCH | 0.09 ± 0.04 | 0.11 ± 0.07 | 0.09 ± 0.04 | 1.10 ± 0.8××,× | |
| RCH | 0.15 ± 0.06 | 0.46 ± 0.38* | 0.32 ± 0.23 | 1.23 ± 0.98××,× | |
| B | 0.12 ± 0.06 | 1.33 ± 1.01* | 1.66 ± 0.93# | 4.09 ± 2.87××,× | |
LCH: left cerebral hemisphere; RCH: right cerebral hemisphere; BS: brain stem; C: cerebellum, B: total brain.
*Group 2 versus Group 1, P ≤ 0.05; #Group 3 versus Group 1, P ≤ 0.05; ×Group 4 versus Group 3, P ≤ 0.05; ##Group 4 versus Group 2, P ≤ 0.05; ××Group 4 versus Group 1, P ≤ 0.05.